Semaglutide delay tests the post-Revlimid bridge
- The main test is whether new products can offset the active Revlimid patent cliff.
- Semaglutide sales in Canada are halted until at least November 2026 due to API manufacturing challenges.
- A June 2026 FDA inspection at the Bachupally biologics facility resulted in a Form 483 with seven observations.
- The Abatacept biosimilar application has an FDA goal date of mid-December 2026.
- Management targets double-digit top-line growth and roughly 25% EBITDA margins over time.
A fragile bridge after Revlimid
Dr. Reddy's is trying to manage a difficult transition. Generic Revlimid was a major profit source, but its January 2026 patent cliff is actively cutting into North American revenue. The company needs new growth drivers to fill that gap.
The bull case relies on consumer health additions in Europe and complex generic launches. The integration of the acquired nicotine replacement therapy business is largely complete and driving strong European growth. Furthermore, the company expects to resume semaglutide supply by November 2026 and aims for Abatacept FDA approval by mid-December 2026.
The bear case centers on severe execution stumbles. Semaglutide sales in Canada were halted due to active pharmaceutical ingredient quality issues, forcing a significant financial provision of INR 240 crores. At the same time, the Bachupally biologics facility received a Form 483 with seven observations in June 2026, which could threaten the timeline for Abatacept and other pipeline biosimilars.
Finn's view is balanced but cautious. The valuation is favorable, but recent performance and sentiment scores reflect the reality of launch delays and quality setbacks during a vulnerable transition period.
Generics cash, harder launches
Dr. Reddy's makes money by selling generic medicines around the world. It also sells active pharmaceutical ingredients and does some contract manufacturing work for other drug companies.
The traditional model leaned on broad generic scale, especially in North America. The newer strategy shifts toward higher-value areas like consumer health, complex generics, innovative products in emerging markets, and biosimilars. This shift is designed to offset normal generic price decay and sudden patent cliffs.
Management wants double-digit sales growth and about 25% EBITDA margins over time. They have also identified a 500 to 600 basis point discretionary cost lever in SG&A and R&D if margins need defense during the transition.
This model breaks if new launches arrive late, price too low, or fail regulatory inspection. It also struggles if the base U.S. generic business erodes faster than Europe, India, and emerging markets can grow.
What fills the medicine cabinet
Global generics
This is the core business of producing copies of branded drugs. North America remains important, but it is under heavy pressure from Revlimid price erosion.
Lenalidomide
Generic Revlimid has been a major contributor, but the patent cliff is now active and reducing North American sales.
Nicotine replacement therapy
The acquired consumer health business in Europe is largely integrated and driving triple-digit regional growth year-over-year.
Semaglutide
Approved in Canada and India for type 2 diabetes. However, Canadian sales are halted due to API manufacturing challenges, pushing meaningful contribution back to late 2026.
Abatacept biosimilar
The IV version has a mid-December 2026 FDA goal date. Approval relies heavily on resolving observations at the Bachupally facility.
Partnered biosimilars
The company has partnered assets such as denosumab and pembrolizumab. Prior complete response letters show that the regulatory path can be uneven.
India brands
India is growing double digits, helped by new launches, volume, and selected brand acquisitions like Stugeron.
Where sales come from
The mix reflects general historical trends outlined by management, where North America is the largest segment but also the most exposed to Revlimid declines.
What can still break
Semaglutide manufacturing execution
High impact · High oddsAPI quality challenges halted Canadian semaglutide sales and forced a massive financial provision. The required growth to offset Revlimid relies heavily on resolving these issues and resuming supply by November 2026.
Biosimilar approval delays
High impact · High oddsThe Bachupally biologics facility received a Form 483 with seven observations in June 2026. This threatens the mid-December 2026 FDA goal date for Abatacept and highlights broader regulatory risks for the biosimilar pipeline.
Revlimid cliff cuts deeper
High impact · High oddsThe January 2026 Revlimid cliff is actively dragging down North America revenue. If the base U.S. business does not stabilize, margin pressure will persist during the transition.
India semaglutide IP loss
Medium impact · Medium oddsDr. Reddy's launched semaglutide in India, but the company is challenging patents in the Delhi High Court. A bad ruling could limit sales or change launch economics in a key early market.
Tariff pressure
Medium impact · Medium oddsPotential U.S. generic or API tariffs could hurt supply chains and margins. Using a U.S. contract manufacturer for Abatacept helps, but it does not remove the risk for the broader generic portfolio.
In one breath
What does Dr. Reddy's Laboratories do?
Dr. Reddy's sells generic medicines, active pharmaceutical ingredients, consumer health products, and biosimilars. Its main markets include North America, Europe, India, and emerging markets.
Why does Revlimid matter so much for RDY?
Revlimid is the branded drug name for lenalidomide, and Dr. Reddy's generic version was a major profit source. The patent cliff began in January 2026, causing more competition and lower prices in North America.
Is semaglutide already approved for Dr. Reddy's?
Yes, it is approved in Canada and India. However, Canadian sales were halted due to manufacturing challenges, and the company aims to resume supply by November 2026.
What is the next big catalyst for RDY?
The key upcoming catalysts are the targeted November 2026 resumption of semaglutide supply and the mid-December 2026 FDA goal date for the Abatacept biosimilar.
